Vascular endothelial dysfunction in diabetic cardiomyopathy: Pathogenesis and potential treatment targets

Pharmacology and Therapeutics

Volumn 111, Issue 2, 2006, Pages 384-399

  Farhangkhoee, Hana ^a   Khan, Zia A ^a,b   Kaur, Harkiran ^a   Xin, Xiping ^a   Chen, Shali ^a   Chakrabarti, Subrata ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Diabetic cardiomyopathy; Dyslipidemia; Endothelial cell damage; Extracellular matrix; Heart failure; Hyperglycemia

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; ALDEHYDE REDUCTASE; ALPHA TOCOPHEROL; AMINOGUANIDINE; ASCORBIC ACID; BETA CAROTENE; FATTY ACID; HEME OXYGENASE; INOSITOL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PONALRESTAT; PROTEIN KINASE C; ROSIGLITAZONE; RUBOXISTAURIN; SORBINIL; SORBITOL; TOLRESTAT; ZOPOLRESTAT;

AEROBIC METABOLISM; CAPILLARY BASEMENT MEMBRANE; CARDIOMYOPATHY; CELL DEATH; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM LESION; ENZYME ACTIVATION; FATTY ACID TRANSPORT; FIBROSIS; GLUCOSE TRANSPORT; GLYCATION; HEMODYNAMICS; HUMAN; HYPERGLYCEMIA; LIPID STORAGE; METABOLISM; MUSCLE CELL; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ANIMALS; CARDIOMYOPATHIES; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; HUMANS; HYPERGLYCEMIA;

EID: 33744782901     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2005.10.008     Document Type: Review

References (199)

1. Abu El-Asrar A.M., Meersschaert A., Dralands L., Missotten L., and Geboes K. Inducible nitric oxide synthase and vascular endothelial growth factor are colocalized in the retinas of human subjects with diabetes. Eye 18 (2004) 306-313
2. Airaksinen K.E., Salmela P.I., Linnaluoto M.K., Ikaheimo M.J., Ahola K., and Ryhanen L.J. Diminished arterial elasticity in diabetes: association with fluorescent advanced glycosylation end products in collagen. Cardiovasc Res 27 (1993) 942-945
3. Ak G., Buyukberber S., Sevinc A., Turk H.M., Ates M., Sari R., et al. The relation between plasma endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with type 2 diabetes mellitus. J Diabetes Its Complicat 15 (2001) 150-157
4. Anguera I., Magrina J., Setoain F.J., Esmatges E., Pare C., Vidal J., et al. Anatomopathological bases of latent ventricular dysfunction in insulin-dependent diabetics. Rev Esp Cardiol 51 (1998) 43-50
5. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens 21 (2003) 3-12
6. Babaei-Jadidi R., Karachalias N., Kupich C., Ahmed N., and Thornalley P.J. High-dose thiamine therapy counters dyslipidaemia in streptozotocin-induced diabetic rats. Diabetologia 47 (2004) 2235-2246
7. Baumgartner I., Rauh G., Pieczek A., Wuensch D., Magner M., Kearney M., et al. Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor. Ann Intern Med 132 (2000) 880-884
8. Baynes J.W., and Thorpe S.R. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48 (1999) 1-9
9. Bell D.S. Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease?. Diabetes Care 18 (1995) 708-714
10. Bogacka I., Xie H., Bray G.A., and Smith S.R. The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. Diabetes Care 27 (2004) 1660-1667
11. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414 (2001) 813-820
12. Brownlee M., Vlassara H., Kooney A., Ulrich P., and Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232 (1986) 1629-1632
13. Brownlee M., Cerami A., and Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318 (1988) 1315-1321
14. Brutsaert D.L. Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiol Rev 83 (2003) 59-115
15. Burg M.B. Molecular basis of osmotic regulation. Am J Physiol 268 (1995) F983-F996
16. Cai L., and Kang Y.J. Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc Toxicol 1 (2001) 181-193
17. Candido R., Forbes J.M., Thomas M.C., Thallas V., Dean R.G., Burns W.C., et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 18 (2003) 785-792
18. Carvajal K., and Moreno-Sanchez R. Heart metabolic disturbances in cardiovascular diseases. Arch Med Res 34 (2003) 89-99
19. Chakrabarti S., and Sima A.A. The effect of myo-inositol treatment on basement membrane thickening in the BB/W-rat retina. Diabetes Res Clin Pract 16 (1992) 13-17
20. Chandra D., Jackson E.B., Ramana K.V., Kelley R., Srivastava S.K., and Bhatnagar A. Nitric oxide prevents aldose reductase activation and sorbitol accumulation during diabetes. Diabetes 51 (2002) 3095-3101
21. Chen S., Evans T., Mukherjee K., Karmazyn M., and Chakrabarti S. Diabetes-induced myocardial structural changes: role of endothelin-1 and its receptors. J Mol Cell Cardiol 32 (2000) 1621-1629
22. Chen S., Khan Z.A., Cukiernik M., and Chakrabarti S. Differential activation of NF-kappa B and AP-1 in increased fibronectin synthesis in target organs of diabetic complications. Am J Physiol 284 (2003) E1089-E1097
23. Chen S., Mukherjee S., Chakraborty C., and Chakrabarti S. High glucose-induced, endothelin-dependent fibronectin synthesis is mediated via NF-kappa B and AP-1. Am J Physiol 284 (2003) C263-C272
24. Chen S., Khan Z.A., Barbin Y., and Chakrabarti S. Pro-oxidant role of heme oxygenase in mediating glucose-induced endothelial cell damage. Free Radic Res 38 (2004) 1301-1310
25. Chou E., Suzuma I., Way K.J., Opland D., Clermont A.C., Naruse K., et al. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 105 (2002) 373-379
26. Collier A., Leach J.P., McLellan A., Jardine A., Morton J.J., and Small M. Plasma endothelin-like immunoreactivity levels in IDDM patients with microalbuminuria. Diabetes Care 15 (1992) 1038-1040
27. Consensus statement, and American Diabetes Association. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 16 (1993) 72-78
28. Cooper M.E. Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. Am J Hypertens 17 (2004) 31S-38S
29. Cosentino F., and Katusic Z.S. Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries. Circulation 91 (1995) 139-144
30. Cosson S., and Kevorkian J.P. Left ventricular diastolic dysfunction: an early sign of diabetic cardiomyopathy?. Diabetes Metab 29 (2003) 455-466
31. Cukiernik M., Mukherjee S., Downey D., and Chakabarti S. Heme oxygenase in the retina in diabetes. Curr Eye Res 27 (2003) 301-308
32. D'Amico M., Marfella R., Nappo F., Di Filippo C., De Angelis L., Berrino L., et al. High glucose induces ventricular instability and increases vasomotor tone in rats. Diabetologia 44 (2001) 464-470
33. Das S.R., Drazner M.H., Yancy C.W., Stevenson L.W., Gersh B.J., and Dries D.L. Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention trial. Am Heart J 148 (2004) 883-888
34. Decker P., and Muller S. Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress. Curr Pharm Biotechnol 3 (2002) 275-283
35. de Kreutzenberg S.V., Crepaldi C., Marchetto S., Calo L., Tiengo A., Del Prato S., et al. Plasma free fatty acids and endothelium-dependent vasodilation: effect of chain-length and cyclooxygenase inhibition. J Clin Endocrinol Metab 85 (2000) 793-798
36. Demaine A.G. Polymorphisms of the aldose reductase gene and susceptibility to diabetic microvascular complications. Curr Med Chem 10 (2003) 1389-1398
37. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
38. Di Mario U., and Pugliese G. 15th Golgi lecture: from hyperglycaemia to the dysregulation of vascular remodelling in diabetes. Diabetologia 44 (2001) 674-692
39. Dogra G., Rich L., Stanton K., and Watts G.F. Endothelium-dependent and independent vasodilation studies at normoglycaemia in type I diabetes mellitus with and without microalbuminuria. Diabetologia 44 (2001) 593-601
40. Donatelli M., Colletti I., Bucalo M.L., Russo V., and Verga S. Plasma endothelin levels in NIDDM patients with macroangiopathy. Diabetes Res 25 (1994) 159-164
41. Du X., Matsumura T., Edelstein D., Rossetti L., Zsengeller Z., Szabo C., et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 112 (2003) 1049-1057
42. Duffy S.J., Gokce N., Holbrook M., Huang A., Frei B., Keaney Jr. J.F., et al. Treatment of hypertension with ascorbic acid. Lancet 354 (1999) 2048-2049
43. Dvornik D. Aldose reductase inhibitors as pathobiochemical probes. J Diabetes Its Complicat 6 (1992) 25-34
44. Dyer D.G., Dunn J.A., Thorpe S.R., Bailie K.E., Lyons T.J., McCance D.R., et al. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 91 (1993) 2463-2469
45. Endemann G., Stanton L.W., Madden K.S., Bryant C.M., White R.T., and Protter A.A. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem 268 (1993) 11811-11816
46. Factor S.M., Minase T., and Sonnenblick E.H. Clinical and morphological features of human hypertensive-diabetic cardiomyopathy. Am Heart J 99 (1980) 446-458
47. Factor S.M., Okun E.M., and Minase T. Capillary microaneurysms in the human diabetic heart. N Engl J Med 302 (1980) 384-388
48. Factor S.M., Bhan R., Minase T., Wolinsky H., and Sonnenblick E.H. Hypertensive diabetic cardiomyopathy in the rat: an experimental model of human disease. Am J Pathol 102 (1981) 219-228
49. Fang Z.Y., Prins J.B., and Marwick T.H. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 25 (2004) 543-567
50. Farhangkhoee H., Khan Z.A., Mukherjee S., Cukiernik M., Barbin Y.P., Karmazyn M., et al. Heme oxygenase in diabetes-induced oxidative stress in the heart. J Mol Cell Cardiol 35 (2003) 1439-1448
51. Farhangkhoee H., Khan Z.A., Barbin Y.P., and Chakrabarti S. Glucose-induced upregulation of CD36 mediates oxidative stress and microvascular endothelial cell dysfunction. Diabetologia 48 (2005) 1401-1410
52. Feener E.P., and King G.L. Endothelial dysfunction in diabetes mellitus: role in cardiovascular disease. Heart Fail Monit 1 (2001) 74-82
53. Fein F.S., and Sonnenblick E.H. Diabetic cardiomyopathy. Cardiovasc Drugs Ther 8 (1994) 65-73
54. Feron O., Belhassen L., Kobzik L., Smith T.W., Kelly R.A., and Michel T. Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J Biol Chem 271 (1996) 22810-22814
55. Feron O., Saldana F., Michel J.B., and Michel T. The endothelial nitric-oxide synthase-caveolin regulatory cycle. J Biol Chem 273 (1998) 3125-3128
56. Finck B.N., Lehman J.J., Leone T.C., Welch M.J., Bennett M.J., Kovacs A., et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 109 (2002) 121-130
57. Finck B.N., Han X., Courtois M., Aimond F., Nerbonne J.M., Kovacs A., et al. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A 100 (2003) 1226-1231
58. Fleming I., and Busse R. Signal transduction of eNOS activation. Cardiovasc Res 43 (1999) 532-541
59. Fleming I., and Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol 284 (2003) R1-R12
60. Fortuin F.D., Vale P., Losordo D.W., Symes J., DeLaria G.A., Tyner J.J., et al. One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients. Am J Cardiol 92 (2003) 436-439
61. Francis G.A., Annicotte J.-S., and Auwerx J. PPAR-a effects on the heart and other vascular tissues. Am J Physiol 285 (2003) H1-H9
62. Galvez A.S., Ulloa J.A., Chiong M., Criollo A., Eisner V., Barros L.F., et al. Aldose reductase induced by hyperosmotic stress mediates cardiomyocyte apoptosis: differential effects of sorbitol and mannitol. J Biol Chem 278 (2003) 38484-38494
63. Garcia M.J., McNamara P.M., Gordon T., and Kannel W.B. Morbidity and mortality in diabetics in the Framingham population: sixteen year follow-up study. Diabetes 23 (1974) 105-111
64. Gilde A.J., and Bilsen M. Peroxisome proliferator-activated receptors (PPARs): regulators of gene expression in heart and skeletal muscle. Acta Physiol Scand 178 (2003) 425-434
65. Giles T.D., Ouyang J., Kerut E.K., Given M.B., Allen G.E., McIlwain E.F., et al. Changes in protein kinase C in early cardiomyopathy and in gracilis muscle in the BB/Wor diabetic rat. Am J Physiol 274 (1998) H295-H307
66. Gonzalez R.G., Barnett P., Aguayo J., Cheng H.M., and Chalack L.T. Direct measurement of polyol pathway activity in the ocular lens. Diabetes 33 (1984) 196-199
67. Greene D.A., Chakrabarti S., Lattimer S.A., and Sima A.A. Role of sorbitol accumulation and myo-inositol depletion in paranodal swelling of large myelinated nerve fibers in the insulin-deficient spontaneously diabetic bio-breeding rat. Reversal by insulin replacement, an aldose reductase inhibitor, and myo-inositol. J Clin Invest 79 (1987) 1479-1485
68. Griendling K.K., and FitzGerald G.A. Oxidative stress and cardiovascular injury: I. Basic mechanisms and in vivo monitoring of ROS. Circulation 108 (2003) 1912-1916
69. Guo M., Wu M.H., Korompai F., and Yuan S.Y. Upregulation of PKC genes and isozymes in cardiovascular tissues during early stages of experimental diabetes. Physiol Genomics 12 (2003) 139-146
70. Guzik T.J., Mussa S., Gastaldi D., Sadowski J., Ratnatunga C., Pillai R., et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105 (2002) 1656-1662
71. Haak T., Jungmann E., Felber A., Hillmann U., and Usadel K.H. Increased plasma levels of endothelin in diabetic patients with hypertension. Am J Hypertens 5 (1992) 161-166
72. Hallsten K., Virtanen K.A., Lonnqvist F., Janatuinen T., Turiceanu M., Ronnemaa T., et al. Enhancement of insulin-stimulated myocardial glucose uptake in patients with type 2 diabetes treated with rosiglitazone. Diabet Med 21 (2004) 1280-1287
73. Hamby R.I., Zoneraich S., and Sherman L. Diabetic cardiomyopathy. JAMA 229 (1974) 1749-1754
74. Hammes H.P., Du X., Edelstein D., Taguchi T., Matsumura T., Ju Q., et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9 (2003) 294-299
75. Hayat S.A., Patel B., Khattar R.S., and Malik R.A. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci (Lond) 107 (2004) 539-557
76. Hedman M., Hartikainen J., Syvanne M., Stjernvall J., Hedman A., Kivela A., et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: Phase II. Results of the Kuopio Angiogenesis Trial (KAT). Circulation 107 (2003) 2677-2683
77. Henderson A.H. 'It all used to be so simple in the old days'; a personal view. Eur Heart J 22 (2001) 648-653
78. Hoeldtke R.D., Bryner K.D., McNeill D.R., Hobbs G.R., and Baylis C. Peroxynitrite versus nitric oxide in early diabetes. Am J Hypertens 16 (2003) 761-766
79. Hopfner R.L., Hasnadka R.V., Wilson T.W., McNeill J.R., and Gopalakrishnan V. Insulin increases endothelin-1-evoked intracellular free calcium responses by increased ET(A) receptor expression in rat aortic smooth muscle cells. Diabetes 47 (1998) 937-944
80. Hotta N. New concepts and insights on pathogenesis and treatment of diabetic complications: polyol pathway and its inhibition. Nagoya J Med Sci 60 (1997) 89-100
81. Inoguchi T., Battan R., Handler E., Sportsman J.R., Heath W., and King G.L. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci U S A 89 (1992) 11059-11063
82. Inoguchi T., Li P., Umeda F., Yu H.Y., Kakimoto M., Imamura M., et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49 (2000) 1939-1945
83. Inoguchi T., Sonta T., Tsubouchi H., Etoh T., Kakimoto M., Sonoda N., et al. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc Nephrol 14 (2003) S227-S232
84. Ishii H., Jirousek M.R., Koya D., Takagi C., Xia P., Clermont A., et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 272 (1996) 728-731
85. Isner J.M., Ropper A., and Hirst K. VEGF gene transfer for diabetic neuropathy. Hum Gene Ther 12 (2001) 1593-1594
86. Iwanaga Y., Kihara Y., Hasegawa K., Inagaki K., Yoneda T., Kaburagi S., et al. Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to congestive heart failure in salt-sensitive hypertensive rats. Circulation 98 (1998) 2065-2073
87. Jain S.K., McVie R., Jaramillo J.J., Palmer M., Smith T., Meachum Z.D., et al. The effect of modest vitamin E supplementation on lipid peroxidation products and other cardiovascular risk factors in diabetic patients. Lipids 31 (1996) S87-S90
88. Joffe I.I., Travers K.E., Perreault-Micale C.L., Hampton T., Katz S.E., Morgan J.P., et al. Abnormal cardiac function in the streptozotocin-induced non-insulin-dependent diabetic rat: noninvasive assessment with Doppler echocardiography and contribution of the nitric oxide pathway. J Am Coll Cardiol 34 (1999) 2111-2119
89. John W.G., and Lamb E.J. The Maillard or browning reaction in diabetes. Eye 7 (1993) 230-237
90. Johnson B.F., Nesto R.W., Pfeifer M.A., Slater W.R., Vinik A.I., Chyun D.A., et al. Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitor administration. Diabetes Care 27 (2004) 448-454
91. Johnstone M.T., Creager S.J., Scales K.M., Cusco J.A., Lee B.K., and Creager M.A. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 88 (1993) 2510-2516
92. Kador P.F., Robison W.G.Jr., and Kinoshita J.H. The pharmacology of aldose reductase inhibitors. Annu Rev Pharmacol Toxicol 25 (1985) 691-714
93. Kakizawa H., Itoh M., Itoh Y., Imamura S., Ishiwata Y., Matsumoto T., et al. The relationship between glycemic control and plasma vascular endothelial growth factor and endothelin-1 concentration in diabetic patients. Metabolism 53 (2004) 550-555
94. Kass D.A., Shapiro E.P., Kawaguchi M., Capriotti A.R., Scuteri A., deGroof R.C., et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 104 (2001) 1464-1470
95. Kawaguchi M., Techigawara M., Ishihata T., Saito F., Maehara K., and Maruyama Y. A comparison of ultrastructural changes on endomyocardial biopsy specimens obtained from patients with and without diabetes mellitus with and without hypertension. Heart Vessels 12 (1997) 267-274
96. Khan Z.A., and Chakrabarti S. Endothelins in chronic diabetic complications. Can J Physiol Pharmacol 81 (2003) 622-634
97. Khan Z.A., and Chakrabarti S. Growth factors in proliferative diabetic retinopathy. Exp Diabesity Res 4 (2003) 287-301
98. Khan Z.A., Cukiernik M., Gonder J.R., and Chakrabarti S. Oncofetal fibronectin in diabetic retinopathy. Invest Ophthalmol Vis Sci 45 (2004) 287-295
99. Khan Z.A., Barbin Y.P., Farhangkhoee H., Beier N., Scholz W., and Chakrabarti S. Glucose-induced serum-and glucocorticoid-regulated kinase activation in oncofetal fibronectin expression. Biochem Biophys Res Commun 329 (2005) 275-280
100. Kim F., Tysseling K.A., Rice J., Pham M., Haji L., Gallis B.M., et al. Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta. Arterioscler Thromb Vasc Biol 25 (2005) 989-994
101. King G.L., and Loeken M.R. Hyperglycemia-induced oxidative stress in diabetic complications. Histochem Cell Biol 122 (2004) 333-338
102. Kolsut P., Malecki M., Zelazny P., Teresinska A., Firek B., Janik P., et al. Gene therapy of coronary artery disease with phvegf165-early outcome. Kardiol Pol 59 (2003) 373-384
103. Kouvaras G., Cokkinos D., and Spyropoulou M. Increased mortality of diabetics after acute myocardial infarction attributed to diffusely impaired left ventricular performance as assessed by echocardiography. Jpn Heart J 29 (1988) 1-9
104. Koya D., and King G.L. Protein kinase C activation and the development of diabetic complications. Diabetes 47 (1998) 859-866
105. Lambert J., Aarsen M., Donker A.J., and Stehouwer C.D. Endothelium-dependent and-independent vasodilation of large arteries in normoalbuminuric insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 16 (1996) 705-711
106. Lariviere R., Deng L.Y., Day R., Sventek P., Thibault G., and Schiffrin E.L. Increased endothelin-1 gene expression in the endothelium of coronary arteries and endocardium in the DOCA-salt hypertensive rat. J Mol Cell Cardiol 27 (1995) 2123-2131
107. La Selva M., Beltramo E., Passera P., Porta M., and Molinatti G.M. The role of endothelium in the pathogenesis of diabetic microangiopathy. Acta Diabetol 30 (1993) 190-200
108. Lee C.-H., Olson P., and Evans R.M. Lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144 (2003) 2201-2207
109. Lewinter M.M. Diabetic cardiomyopathy: an overview. Coron Artery Dis 7 (1996) 95-98
110. Li S.H., and McNeill J.H. In vivo effects of vanadium on GLUT4 translocation in cardiac tissue of STZ-diabetic rats. Mol Cell Biochem 217 (2001) 121-129
111. Lisanti M.P., Scherer P.E., Vidugiriene J., Tang Z., Hermanowski-Vosatka A., Tu Y.H., et al. Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease. J Cell Biol 126 (1994) 111-126
112. Liu X., Wang J., Takeda N., Binaglia L., Panagia V., and Dhalla N.S. Changes in cardiac protein kinase C activities and isozymes in streptozotocin-induced diabetes. Am J Physiol 277 (1999) E798-E804
113. Liu J., Masurekar M.R., Vatner D.E., Jyothirmayi G.N., Regan T.J., Vatner S.F., et al. Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. Am J Physiol 285 (2003) H2587-H2591
114. Liu Y., Zhu Y., Rannou F., Lee T.S., Formentin K., Zeng L., et al. Laminar flow activates peroxisome proliferator-activated receptor-gamma in vascular endothelial cells. Circulation 110 (2004) 1128-1133
115. Lomuscio A., Castagnone M., Vergani D., Verzoni A., Beltrami A., Ravaglia R., et al. Clinical correlation between diabetic and non diabetic patients with myocardial infarction. Acta Cardiol 46 (1991) 543-554
116. Losordo D.W., Vale P.R., Symes J.F., Dunnington C.H., Esakof D.D., Maysky M., et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98 (1998) 2800-2804
117. Losordo D.W., Vale P.R., Hendel R.C., Milliken C.E., Fortuin F.D., Cummings N., et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 105 (2002) 2012-2018
118. Maines M.D. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 37 (1997) 517-554
119. Malhotra A., Begley R., Kang B.P., Rana I., Liu J., Yang G., et al. PKC{epsilon} dependent survival signals in the diabetic heart. Am J Physiol (2005) 10.1152/ajpheart.01200.2004
120. Marchioli R. Antioxidant vitamins and prevention of cardiovascular disease: laboratory, epidemiological and clinical trial data. Pharmacol Res 40 (1999) 227-238
121. Masutani M., Suzuki H., Kamada N., Watanabe M., Ueda O., Nozaki T., et al. Poly(ADP-ribose) polymerase gene disruption conferred mice resistant to streptozotocin-induced diabetes. Proc Natl Acad Sci U S A 96 (1999) 2301-2304
122. Maxwell S.R.J. Antioxidant vitamin supplements. Drug Safety 21 (1999) 253-266
123. Mbanya J.C., Sobngwi E., Mbanya D.S., and Ngu K.B. Left ventricular mass and systolic function in African diabetic patients: association with microalbuminuria. Diabetes Metab 27 (2001) 378-382
124. McCance D.R., Dyer D.G., Dunn J.A., Bailie K.E., Thorpe S.R., Baynes J.W., et al. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 91 (1993) 2470-2478
125. McVeigh G.E., Brennan G.M., Johnston G.D., McDermott B.J., McGrath L.T., Henry W.R., et al. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35 (1992) 771-776
126. Mebazaa A., Mayoux E., Maeda K., Martin L.D., Lakatta E.G., Robotham J.L., et al. Paracrine effects of endocardial endothelial cells on myocyte contraction mediated via endothelin. Am J Physiol 265 (1993) H1841-H1846
127. Mellor H., and Parker P.J. The extended protein kinase C superfamily. Biochem J 332 (1998) 281-292
128. Miyata T., Kurokawa K., and Van Ypersele De Strihou C. Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. J Am Soc Nephrol 9 (2000) 1744-1752
129. Nakayama H., Morozumi T., Nanto S., Shimonagata T., Ohara T., Takano Y., et al. Abnormal myocardial free fatty acid utilization deteriorates with morphological changes in the hypertensive heart. Jpn Circ J 9 (2001) 783-787
130. Nishikawa T., Edelstein D., Du X.L., Yamagishi S.-I., Matsumura T., Kaneda Y., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404 (2000) 787-790
131. Nishimura T., Yamada H., Kinoshita M., and Ochi J. Endothelin expression during rat heart development: an immunohistochemical and in situ hybridization study. Biomed Res 15 (1994) 291-298
132. Norton G.R., Candy G., and Woodiwiss A.J. Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation 93 (1996) 1905-1912
133. Nunoda S., Genda A., Sugihara N., Nakayama A., Mizuno S., and Takeda R. Quantitative approach to the histopathology of the biopsied right ventricular myocardium in patients with diabetes mellitus. Heart Vessels 1 (1985) 43-47
134. Ogita H., and Liao J. Endothelial function and oxidative stress. Endothelium 11 (2004) 123-132
135. Okada H., Woodcock-Mitchell J., Mitchell J., Sakamoto T., Marutsuka K., Sobel B.E., et al. Induction of plasminogen activator inhibitor type 1 and type 1 collagen expression in rat cardiac microvascular endothelial cells by interleukin-1 and its dependence on oxygen-centered free radicals. Circulation 97 (1998) 2175-2182
136. Okruhlicova L., Tribulova N., Weismann P., and Sotnikova R. Ultrastructure and histochemistry of rat myocardial capillary endothelial cells in response to diabetes and hypertension. Cell Res 15 (2005) 532-538
137. Ommen S.R., and Nishimura R.A. A clinical approach to the assessment of left ventricular diastolic function by Doppler echocardiography: update 2003. Heart 89 (2003) 18-23
138. Pacher P., Liaudet L., Soriano F.G., Mabley J.G., Szabo E., and Szabo C. The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 51 (2002) 514-521
139. Petrova R., Yamamoto Y., Muraki K., Yonekura H., Sakurai S., and Watanabe T. Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes. J Mol Cell Cardiol 34 (2002) 1425-1431
140. Pfeifer M.A., Schumer M.P., and Gelber D.A. Aldose reductase inhibitors: the end of an era or the need for different trial designs?. Diabetes 46 (1997) S82-S89
141. Pieper A.A., Brat D.J., Krug D.K., Watkins C.C., Gupta A., Blackshaw S., et al. Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes. Proc Natl Acad Sci U S A 96 (1999) 3059-3064
142. Popov D., Sima A., Stern D., and Simionescu M. The pathomorphological alterations of endocardial endothelium in experimental diabetes and diabetes associated with hyperlipidemia. Acta Diabetol 33 (1996) 41-47
143. Pou S., Pou W.S., Bredt D.S., Snyder S.H., and Rosen G.M. Generation of superoxide by purified brain nitric oxide synthase. J Biol Chem 267 (1992) 24173-24176
144. Pou S., Keaton L., Surichamorn W., and Rosen G.M. Mechanism of superoxide generation by neuronal nitric-oxide synthase. J Biol Chem 274 (1999) 9573-9580
145. Pugliese G., Pricci F., Romeo G., Pugliese F., Mene P., Giannini S., et al. Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. Diabetes 46 (1997) 1881-1887
146. Punzengruber C., and Schernthaner G. Diastolic abnormalities might precede systolic abnormalities of left ventricular function in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 29 (1986) 343
147. Raj D.S., Choudhury D., Welbourne T.C., and Levi M. Advanced glycation end products: a nephrologist's perspective. Am J Kidney Dis 35 (2000) 365-380
148. Ramasamy R., Oates P.J., and Schaefer S. Aldose reductase inhibition protects diabetic and non-diabetic rat hearts from ischemic injury. Diabetes 46 (1997) 292-300
149. Ramasamy R., Trueblood N., and Schaefer S. Metabolic effects of aldose reductase inhibition during low-flow ischemia and reperfusion. Am J Physiol 275 (1998) H195-H203
150. Rodrigues B., Cam M.C., and McNeill J.H. Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem 180 (1998) 53-57
151. Rosano G.M., Vitale C., Sposato B., Mercuro G., and Fini M. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol 28 (2003) 16
152. Rosengart T.K., Lee L.Y., Patel S.R., Sanborn T.A., Parikh M., Bergman G.W., et al. Angiogenesis gene therapy: Phase I. Assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100 (1999) 468-474
153. Roy T.M., Broadstone V.L., Peterson H.R., Snider H.L., Cyrus J., Fell R., et al. The effect of an aldose reductase inhibitor on cardiovascular performance in patients with diabetes mellitus. Diabetes Res Clin Pract 10 (1990) 91-97
154. Rubler S., Dlugash J., Yuceoglu Y.Z., Kumral T., Branwood A.W., and Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30 (1972) 595-602
155. Saito F., Kawaguchi M., Izumida J., Asakura T., Maehara K., and Maruyama Y. Alteration in haemodynamics and pathological changes in the cardiovascular system during the development of Type 2 diabetes mellitus in OLETF rats. Diabetologia 46 (2003) 1161-1169
156. Satoh M., Fujimoto S., Haruna Y., Arakawa S., Horike H., Komai N., et al. NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol 288 (2005) F1144-F1152
157. Savage M.P., Krolewski A.S., Kenien G.G., Lebeis M.P., Christlieb A.R., and Lewis S.M. Acute myocardial infarction in diabetes mellitus and significance of congestive heart failure as a prognostic factor. Am J Cardiol 62 (1988) 665-669
158. Sheetz M.J., and King G.L. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 288 (2002) 2579-2588
159. Shehadeh A., and Regan T.J. Cardiac consequences of diabetes mellitus. Clin Cardiol 18 (1995) 301-305
160. Shen G.X. Selective protein kinase C inhibitors and their applications. Curr Drug Targets Cardiovasc Haematol Disord 3 (2003) 301-307
161. Sicree R., Shaw J., Zimmet P., and Tapp R. The global burden of diabetes. In: Gan D. (Ed). Diabetes atlas 2003. 2nd ed. (2003), International Diabetes Federation, Brussels, Belgium 15-71
162. Sivenius K., Niskanen L., Voutilainen-Kaunisto R., Laakso M., and Uusitupa M. Aldose reductase gene polymorphisms and susceptibility to microvascular complications in Type 2 diabetes. Diabet Med 21 (2004) 1325-1333
163. Skovsted I.C., Christensen M., Breinholt J., and Mortensen S.B. Characterisation of a novel AGE-compound derived from lysine and 3-deoxyglucosone. Cell Mol Biol 44 (1998) 1159-1163
164. Sonta T., Inoguchi T., Tsubouchi H., Sekiguchi N., Kobayashi K., Matsumoto S., et al. Evidence for contribution of vascular NAD(P)H oxidase to increased oxidative stress in animal models of diabetes and obesity. Free Radic Biol Med 37 (2004) 115-123
165. Srivastava S.K., Ansari N.H., Liu S., Izban A., Das B., Szabo G., et al. The effect of oxidants on biomembranes and cellular metabolism. Mol Cell Biochem 19 (1989) 149-157
166. Srivastava S.K., Ramana K.V., Chandra D., Srivastava S., and Bhatnagar A. Regulation of aldose reductase and the polyol pathway activity by nitric oxide. Chem Biol Interact 143-144 (2003) 333-340
167. Srivastava S.K., Ramana K.V., and Bhatnagar A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr Rev 26 (2005) 380-392
168. Stanley W.C., and Marzilli M. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine. Fundam Clin Pharmacol 17 (2003) 133-145
169. Steinberg H.O., Paradisi G., Hook G., Crowder K., Cronin J., and Baron A.D. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes 49 (2000) 1231-1238
170. Sutherland C.G., Fisher B.M., Frier B.M., Dargie H.J., More I.A., and Lindop G.B. Endomyocardial biopsy pathology in insulin-dependent diabetic patients with abnormal ventricular function. Histopathology 14 (1989) 593-602
171. Szabo C. PARP as a drug target for the therapy of diabetic cardiovascular dysfunction. Drug News Perspect 4 (2002) 197-205
172. The PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 54 (2005) 2188-2197
173. Thornalley P.J. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol 44 (1998) 1013-1023
174. Timimi F.K., Ting H.H., Haley E.A., Roddy M.A., Ganz P., and Creager M.A. Vitamin C improves endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol 31 (1998) 552-557
175. Ting H.H., Timimi F.K., Boles K.S., Creager S.J., Ganz P., and Creager M.A. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 97 (1996) 22-28
176. Tomlinson D.R. Mitogen-activated protein kinases as glucose transducers for diabetic complications. Diabetologia 42 (1999) 1271-1281
177. Trueblood N., and Ramasamy R. Aldose reductase inhibition improves altered glucose metabolism of isolated diabetic rat hearts. Am J Physiol 275 (1998) H75-H83
178. Tsai S.C., and Burnakis T.G. Aldose reductase inhibitors: an update. Ann Pharmacother 27 (1993) 751-754
179. Uittenbogaard A., Shaul P.W., Yuhanna I.S., Blair A., and Smart E.J. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem 275 (2000) 11278-11283
180. United Kingdom prospective diabetic study. Lancet 352 (1996) 837-853
181. van de Ree M.A., Huisman M.V., de Man F.H., van der Vijver J.C., Meinders A.E., and Blauw G.J. Impaired endothelium-dependent vasodilation in type 2 diabetes mellitus and the lack of effect of simvastatin. Cardiovasc Res 52 (2001) 299-305
182. Vitale C., Wajngaten M., Sposato B., Gebara O., Rossini P., Fini M., et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 25 (2004) 1814-1821
183. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes/Metab Res Rev 17 (2001) 436-443
184. Wakasaki H., Koya D., Schoen F.J., Jirousek M.R., Ways D.K., Hoit B.D., et al. Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proc Natl Acad Sci U S A 19 (1997) 9320-9325
185. Wang Y., Ng M.C., Lee S.C., So W.Y., Tong P.C., and Cockram C.S. Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes. Diabetes Care 26 (2003) 2410-2415
186. Wang G., Wei J., Guan Y., Jin N., Mao J., and Wang X. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. Metabolism 54 (2005) 590-597
187. Wautier M.P., Chappey O., Corda S., Stern D.M., Schmidt A.M., and Wautier J.L. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol 280 (2001) E685-E694
188. Way K.J., Katai N., and King G.L. Protein kinase C and the development of diabetic vascular complications. Diabet Med 18 (2001) 945-959
189. Way K.J., Isshiki K., Suzuma K., Yokota T., Zvagelsky D., Schoen F.J., et al. Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes 51 (2002) 2709-2718
190. Wheeler G.D. Ruboxistaurin (Eli Lilly). IDrugs 6 (2003) 159-163
191. Williamson J.R., Chang K., Frangos M., Hasan K.S., Ido Y., Kawamura T., et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42 (1993) 801-813
192. Wold L.E., and Ren J. Streptozotocin directly impairs cardiac contractile function in isolated ventricular myocytes via a p38 map kinase-dependent oxidative stress mechanism. Biochem Biophys Res Commun 318 (2004) 1066-1071
193. Xin X., Khan Z.A., Chen S., and Chakrabarti S. Extracellular signal-regulated kinase (ERK) in glucose-induced and endothelin-mediated fibronectin synthesis. Lab Invest 84 (2004) 1451-1459
194. Xin X., Khan Z.A., Chen S., and Chakrabarti S. Glucose-induced Akt1 activation mediates fibronectin synthesis in endothelial cells. Diabetologia (2005) 10.1007/s00125-005-1939-4
195. Yarom R., Zirkin H., Stammler G., and Rose A.G. Human coronary microvessels in diabetes and ischaemia. Morphometric study of autopsy material. J Pathol 166 (1992) 265-270
196. Yasuda I., Kawakami K., Shimada T., Tanigawa K., Murakami R., Izumi S., et al. Systolic and diastolic left ventricular dysfunction in middle-aged asymptomatic non-insulin-dependent diabetics. J Cardiol 22 (1992) 427-438
197. Yoon Y.S., Uchida S., Masuo O., Cejna M., Park J.S., Gwon H.C., et al. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation 111 (2005) 2073-2085
198. Yuan S.Y., Ustinova E.E., Wu M.H., Tinsley J.H., Xu W., Korompai F.L., et al. Protein kinase C activation contributes to microvascular barrier dysfunction in the heart at early stages of diabetes. Circ Res 87 (2000) 412-417
199. Zile M.R., Baicu C.F., and Gaasch W.H. Diastolic heart failure: abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 350 (2004) 1953-1959